This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Eastman (EMN) Gains on Cost Cuts & Innovation Amid Demand Woes
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions, acquisitions and innovation amid challenges from weak demand in certain markets.
Chemours (CC) Opens Cutting-Edge Facility for EV Batteries
by Zacks Equity Research
Chemours (CC) opens the Chemours Battery Innovation Center to advance sustainable battery technology for electric vehicles.
Are Options Traders Betting on a Big Move in Celanese (CE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Celanese (CE) stock based on the movements in the options market lately.
Celanese (CE) Q2 Earnings and Sales Fall Short of Estimates
by Zacks Equity Research
The decline in net sales of Celanese (CE) in Q2 is a result of a decrease in pricing.
Celanese (CE) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Celanese (CE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Celanese (CE) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Celanese (CE) delivered earnings and revenue surprises of -15% and 2.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 4 Chemical Stocks Hit Targets This Earnings Season?
by Anindya Barman
Chemical companies are expected to have benefited from demand recovery across key end markets and moderated de-stocking activities. Let's see how APD, CE, CC and AXTA are poised ahead of their earnings releases.
Unveiling Celanese (CE) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Celanese (CE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Green Plains Renewable Energy (GPRE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Green Plains (GPRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celanese (CE) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Celanese's (CE) investment in high-return organic projects, cost-cutting initiatives, and acquisition synergies are likely to have contributed to its Q2 performance amid demand and pricing headwinds.
Celanese (CE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Celanese (CE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold Onto Celanese (CE) Stock for Now
by Zacks Equity Research
Celanese (CE) benefits from its productivity measures, investments in organic projects, expansion actions and strategic acquisitions amid headwinds from demand softness and pricing pressures.
Zacks Industry Outlook Highlights PPG Industries, Celanese and Axalta Coating
by Zacks Equity Research
PPG Industries, Celanese and Axalta Coating have been highlighted in this Industry Outlook article.
Here's Why Celanese (CE) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Chemical Specialty Stocks to Escape Industry Headwinds
by Anindya Barman
Soft end-market demand and customer de-stocking mar the prospects of the Zacks Chemicals Specialty industry. PPG, CE and AXTA are set to gain from strategic actions to navigate the ongoing challenges.
Celanese (CE) Gains on Cost Actions Amid Demand & Pricing Woes
by Anindya Barman
While Celanese (CE) faces headwinds from soft demand and pricing, it benefits from productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Declares Force Majeure Due to Supply Disruptions
by Zacks Equity Research
Celanese (CE) declares force majeure for acetic acid and VAM, expects a 15-20% production impact in the second quarter and takes costly measures to minimize customer impact.
Celanese (CE) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Celanese (CE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
While Celanese (CE) faces challenges from demand softness and pricing pressures, it benefits from strategic acquisitions, expansion moves and productivity measures.
Why Celanese (CE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Hawkins (HWKN) Earnings Lag Estimates in Q4, Revenues Beat
by Zacks Equity Research
Hawkins (HWKN) sees strong growth in the Water Treatment segment in the fiscal fourth quarter.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Basic Materials Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
American Vanguard (AVD) Q1 Earnings Beat, Sales Miss Estimates
by Zacks Equity Research
American Vanguard's (AVD) U.S. crop business registers strong sales of granular soil insecticides, herbicides and cotton and peanut products in Q1.
Innospec's (IOSP) Q1 Earnings Surpass Estimates, Sales Lag
by Zacks Equity Research
Strong results in the Performance Chemicals segment drove Innospec's (IOSP) earnings in Q1.